News

Lundbeckfonden Ventures News

Chapel Hill, NC and Ness Ziona, Israel – February 14, 2019 – Atox Bio, a clinical stage company developing novel therapies for critically ill patients, today announced the appointment of Robert Greif as Chief Commercial Officer. In this newly created position, Robert will be responsible for building the commercial organization and pre-commercial activities for Reltecimod,...
Lund, Sweden, 08.00 CET, 08 February 2019 – BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, today announces the publication of ground-breaking data on bone remodeling of CERAMENT in pre-clinical model. The study ‘Establishment and effects of allograft and synthetic bone graft substitute treatment of a critical size metaphyseal bone defect...
CAMBRIDGE, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, today announced the acceptance by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for SPR994,...
Lund, Sweden, 08.00 CET, 1 February 2019 – BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, today announces two oral presentations, and three poster presentations at the upcoming Orthopaedic Research Society (ORS) 2019 Annual Meeting. The meeting takes place from February 2-5 at the Austin Convention Center in Austin, Texas and...
Advancing FUROSCIX® with the SmartDose® Drug Delivery System – Forecast 2018 year-end cash of $82 – $87 million and 2019 expenditures of $8 – $10 million per quarter BURLINGTON, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of...
CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections, announced today that it has initiated a Phase 1 clinical trial of SPR720, an orally administered antimicrobial agent being developed for the treatment of non-tuberculous mycobacterial (NTM)...
Cambridge, UK and Indianapolis, US – 28 January 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) welcomes an editorial published in the leading peer-reviewed journal Anesthesiology, accompanying the print publication of results from its positive Phase 3 clinical trial of BARHEMSYS™ (intravenous amisulpride) as rescue treatment of established post-operative nausea & vomiting...
CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections, and Everest Medicines announced today that they have entered into a collaboration to develop, manufacture and commercialize SPR206 in Greater China, South Korea and certain...
CAMBRIDGE, Mass. Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it has received written confirmation from the U.S. Food and Drug Administration (FDA) regarding agreement on the design of its Phase 3 registration trials designed to evaluate light-activated AU-011 for the treatment of patients with choroidal...
1 2 3 54

Lundbeckfonden Ventures

News

Atox Bio Announces Appointment of Robert Greif as Chief Commercial Officer
18. February 2019
BONESUPPORT – Publication of pre-clinical study highlighting unique bone remodeling qualities of CERAMENT® in large bone defects
8. February 2019
Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994
4. February 2019